ONCAlert | 2017 San Antonio Breast Cancer Symposium

Significance of KEYNOTE-045 Trial of Pembrolizumab vs Chemotherapy in Urothelial Carcinoma

Published Online:4:03 PM, Wed June 21, 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the KEYNOTE-045 trial, a phase III open-label study of pembrolizumab (Keytruda) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial carcinoma.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.